佛慈制药(002644) - 2017 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2017 was ¥100,995,201.79, representing a 15.97% increase compared to ¥87,084,779.47 in the same period last year[8]. - Net profit attributable to shareholders was ¥13,548,805.79, a significant increase of 46.68% from ¥9,237,246.34 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥13,495,233.94, up 41.02% from ¥9,570,047.92 in the previous year[8]. - The basic earnings per share rose to ¥0.0265, reflecting a 46.41% increase compared to ¥0.0181 in the same period last year[8]. - The net profit attributable to shareholders for the first half of 2017 is expected to be between 33.36 million and 45.49 million CNY, representing a change of 10.00% to 50.00% compared to the same period in 2016[23]. - The net profit for the first half of 2016 was 30.33 million CNY[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,071,810,630.74, an increase of 1.72% from ¥2,036,714,440.09 at the end of the previous year[8]. - The net assets attributable to shareholders increased to ¥1,304,282,069.83, a rise of 1.06% from ¥1,290,583,264.04 at the end of the last year[8]. - Accounts receivable increased by 38.28% to ¥71,014,932.24 from ¥51,356,653.54 year-on-year[15]. Cash Flow and Expenses - The net cash flow from operating activities was ¥14,038,974.88, which is a 13.08% increase from ¥12,414,998.03 in the same period last year[8]. - The income tax expense for the period was ¥2,516,691.90, a 45.58% increase compared to ¥1,728,750.80 in the same period last year[17]. - The company reported a significant increase in employee compensation payable, which rose by 86.88% to ¥4,212,708.26 from ¥2,254,192.19 in the previous year[16]. Future Outlook - The expected increase in performance is attributed to improved internal management and product structure adjustments, leading to growth in main business revenue and gross profit[23]. - The company has enhanced capital management, utilizing idle funds for cash management, resulting in significant investment income[23].